Click Holdings Limited (NASDAQ:CLIK – Get Free Report) was the recipient of a large drop in short interest in the month of June. As of June 30th, there was short interest totaling 37,691 shares, a drop of 38.2% from the June 15th total of 60,989 shares. Approximately 3.3% of the company’s shares are short sold. Based on an average daily volume of 123,258 shares, the short-interest ratio is currently 0.3 days.
Hedge Funds Weigh In On Click
A hedge fund recently bought a new stake in Click stock. Renaissance Technologies LLC acquired a new position in shares of Click Holdings Limited (NASDAQ:CLIK – Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 14,200 shares of the company’s stock, valued at approximately $25,000. Renaissance Technologies LLC owned 1.23% of Click at the end of the most recent quarter.
Click Stock Down 11.6%
Shares of CLIK traded down $0.20 during mid-day trading on Friday, hitting $1.53. 331,416 shares of the company’s stock were exchanged, compared to its average volume of 362,748. The stock’s 50-day moving average is $1.59 and its 200-day moving average is $2.83. Click has a fifty-two week low of $1.32 and a fifty-two week high of $14.40.
Analyst Upgrades and Downgrades
Several analysts recently weighed in on CLIK shares. Wall Street Zen upgraded shares of Click to a “hold” rating in a report on Saturday, June 13th. Weiss Ratings restated a “sell (d)” rating on shares of Click in a research report on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has an average rating of “Sell”.
Read Our Latest Stock Analysis on CLIK
About Click
Click Therapeutics, Inc (NASDAQ: CLIK) is a clinical-stage digital therapeutics company developing software-based treatments for neurological, psychiatric and chronic diseases. Its platform delivers prescription digital therapies via mobile and web applications, combining evidence-based cognitive behavioral interventions, digital monitoring tools and patient engagement techniques. Click’s approach is designed to complement or extend traditional pharmacological and behavioral treatments for conditions such as major depressive disorder, insomnia and tobacco use disorder.
Founded in 2014, Click has progressed multiple programs through randomized controlled trials and regulatory review.
Featured Stories
- Five stocks we like better than Click
- Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop
- Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs?
- The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story
- Why Intuitive Surgical’s Strong Quarter Still Spooked Investors
Receive News & Ratings for Click Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Click and related companies with MarketBeat.com's FREE daily email newsletter.
